India: You Shall Not Pass! A Look At The Recent Ban On Advertising Of Ayurvedic Drugs

The Ministry of Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homeopathy (AYUSH) vide notification G.S.R. 1230(E) on December 21, 2018 has notified the Drugs and Cosmetics (Eleventh Amendment) Rules, 2018 (Amendment) ,which was subsequently published on December 24, 20181. This Amendment seeks to regulate advertisements of Ayurvedic, Unani and Siddha drugs (ASU Drugs) in an attempt to curb misleading advertisements.

This step has been taken in light of the government's reaction to the recent increase in the number of misleading advertisements relating to ASU Drugs. In 2017, the Ministry of AYUSH stated that it had signed a Memorandum of Understanding (MoU) with the Advertising Standards Council of India (ASCI), a self-regulatory organisation for the advertising industry, to monitor misleading advertisements being published in print and TV media.2

In a press release dated February 9, 2018, the Ministry of AYUSH informed the public that it had come across 804 cases of misleading advertisements/claims allegedly of herbal/AYUSH products and services including Ayurvedic medicines between April, 2015 and January, 2018. They were reported by the ASCI and the Grievances Against Misleading Advertisements (GAMA) portal maintained by the Department of Consumer Affairs.3

Regulation of ASU Drugs

In India, the Drugs and Cosmetics Act, 1940 (D&C Act) and the Drugs and Cosmetic Rules, 1945 (D&C Rules) regulate the import, manufacture, distribution, sale, packaging and labelling of drugs, including ASU Drugs, and cosmetics. The regulation of advertisements for drugs, arguably including ASU Drugs, is governed by the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 (DMROA Act) and the Drugs and Magic Remedies (Objectionable Advertisements) Rules, 1955 (DMROA Rules). ASCI is a body that also looks at this aspect though dependant on self-regulation by industry players.

Drugs and Cosmetics (Eleventh Amendment) Rules, 2018

  1. Prohibition of AdvertisementThe Amendment adds Rule 170(1) to the D&C Rules, prohibiting a manufacturer or his agent from publishing any advertisement relating to the use of ASU drugs for diagnosis, cure, mitigation, treatment or prevention of any disease, disorder, syndrome or condition.4
  2. Advance Approval of Advertisements

The Amendment lays down a requirement for a Unique Identification Number (UIN) for advertising any ASU Drug for purposes other than that prohibited under Rule 170(1). Manufacturers of ASU Drugs need to apply to the State Licensing Authority (SLA) for the UIN for the advertisement issued or aired before this notification, within the period of three months from the date of notification of this Amendment.

The application for advertisement can be rejected on multiple grounds including vulgarity or obscenity; or reference to any ASU Drug in terms which suggest or are calculated to lead to the use of that drug or medicine: for the enhancement of height and dimensions or capacity of performance of male or female sexual organs; depiction of photographs or testimonials of celebrities or government officials; reference to any government or autonomous organisation of the government; appearance of a false impression about the true character of the ASU Drug; or misleading or exaggerated claim about the effectiveness of the concerned ASU Drug.

Existing advertisements, which do not fall in the prohibited category, are required to apply for the UIN before April 21, 2019. The SLA has the power to suspend or cancel manufacturing licences if the directions are not followed.5

Legal Issues

The Amendment though passed with the intent to protect consumer interests and regulate the AYUSH industry is ridden with legal infirmities, which we discuss below:

a. Power of the Central Government under section 33N of the D&C Act

The Amendment has been passed by the Ministry of AYUSH in exercise of its powers under section 33N of the D&C, which states as follows:

"Section 33N – Power of Central Government to make rules

(1) The Central Government may, after consultation with, or on the recommendation of, the Board and after previous publication by notification in the Official Gazette, make rules for the purpose of giving effect to the provisions of this Chapter."

Accordingly, the Central Government's power under section 33N must be exercised with the purpose of giving effect to the provisions of Chapter IVA of the D&C Act, which deals with the regulation of import, manufacture, sale and distribution of drugs and cosmetics including ASU drugs. Advertising of drugs, which is subject matter of regulation under the DMROA Act, lies outside the purview of the said chapter and even outside the ambit of the D&C Act and Rules.

The Amendment, however, seeks to regulate the advertising of drugs that falls under the ambit of the DMROA Act.

b. DMROA Act

The DMROA Act regulates advertising of drugs including ASU drugs. Section 2(b) of the DMROA Act identifies what the said enactment seeks out to regulate i.e:

"'drug' includes-

(i) a medicine for the internal or external use of human beings or animals;

(ii) any substance intended to be used for or in the diagnosis, cure, mitigation, treatment or prevention of disease in human beings or animals;

(iii) any article, other than food, intended to affect or influence in any way the structure or any organic function of the body of human beings or animals;

(iv) any article intended for use as a component of any medicine, substance or article, referred to in sub-clauses (i), (ii) and (iii);"

It can be argued that Section 2(b) would cover ASU drugs as they too are medicines/ substances intended to be used in the diagnosis, cure, mitigation, treatment or prevention of disease in human beings or animals.

Section 3 of the DMROA Act lays down a prohibition against advertisement of certain drugs for treatment of certain diseases. The section reads as follows:

"Section 3 – Prohibition of advertisement of certain drugs for treatment of certain diseases and disorders

Subject to the provisions of this Act, no person shall take any part in the publication of any advertisement referring to any drug in terms which suggest or are calculated to lead to the use of that drug for–

a. the procurement of miscarriage in women or prevention of conception in women; or

b. the maintenance or improvement of the capacity of human beings for sexual pleasure; or

c. the correction of menstrual disorder in women; or

d. the diagnosis, cure, mitigation, treatment or prevention of any disease, disorder or condition specified in the Schedule, or any other disease, disorder or condition (by whatsoever name called) which may be specified in the rules made under this Act:

Provided that no such rule shall be made except-

i. in respect of any disease, disorder or condition which requires timely treatment in consultation with a registered medical practitioner or for which there are normally no accepted remedies; and

ii. after consultation with the Drugs Technical Advisory Board constituted under the Drugs and Cosmetics Act, 1940, and if the Central Government considers necessary, with such other persons having special knowledge or practical experience in respect of Ayurvedic or Unani systems of medicines as that Government deems fit."

The DMROA Act already has provisions pertaining to the prohibition of advertising for drugs that claim treatment of certain diseases – these, arguably, apply to ASU drugs as well. Additionally, the proviso to Section 3 of the DMROA Act states that in case of ASU drugs, the Drugs Technical Advisory Board (DTAB) must be consulted along with persons with special knowledge or practical experience with ASU drugs by the Central Government before making rules under the DMROA Act prohibiting advertisement of any drugs. Therefore, even if an amendment was to be made to the DMROA Act or DMROA Rules under it, the DTAB and persons with specialised knowledge would have to be consulted.

ASU drugs are therefore covered in so far as advertising thereof is concerned. Why then the need for this additional regulation where one exists already?!

c. Fundamental Rights under Article 14 and 19

The Amendment has resulted in an immediate and complete prohibition on advertising by the manufacturers of ASU Drugs while there is no such prohibition for allopathic drugs. The Amendment, as it stands today, is violative of the right to equality guaranteed under Article 14 of the Constitution since it differentiates between allopathic drugs and ASU drugs without any intelligible basis. Further, a complete prohibition against any advertisement is violative of the right to freedom of commercial expression, which has been recognized and protected under Article 19(1)(a). Additionally, the right to practice any profession, or to carry on any occupation, trade or business, which has been guaranteed to such manufacturers, importers, distributors and wholesalers/retailers of ASU drugs under Article 19(1)(a) and 19(1)(g) of the Constitution of India, would also stand violated.

d. Final Rules Different from Draft Rules

The Ministry of AYUSH released draft rules inviting comments and suggestions on a proposed prohibition of advertisements of ASU Drugs vide notification G.S.R. 396 (E) dated April 4, 2016 (Draft Rules). These prohibited publication of any advertisement referring to any ASU Drug that suggest that the use of that drug might lead to diagnosis, cure, mitigation, treatment or prevention of any of the diseases, disorders or conditions in the list. This included an exhaustive list of 37 serious ailments including HIV/AIDS, cancer, deafness, blindness, diabetes mellitus, Parkinson's Disease and cirrhosis etc.

The Amendment, however, envisages a blanket ban on any advertisement proposing cure, mitigation, diagnosis, treatment or prevention of any disease, disorder or condition.

e. Lack of clarity

The procedures prescribed in Rule 170 lack any clarity in that they require an applicant to essentially submit the same data that has already been submitted to the regulator while applying for a manufacturing, sale or import licence under the D&C Act and Rules. The need to provide the same all over again is not justified. That said, the provisions envision a second review of an already granted approval by the same regulatory body. Reasonableness and justification standards for this legislation are therefore not satisfied.

Key takeaways for the industry would be to understand the implications of this Amendment for advertising its ASU drugs. All existing companies are required to apply for a UIN within three months from date of publication of the Amendment. Such a knee-jerk prohibition is bound to cause disruptions in the ASU drug industry. Additionally, it will be interesting to see the impact of this approach to regulate advertising for drugs under the D&C Act and D&C Rules in India. The industry needs to take a look at their marketing and advertising strategy and make necessary adjustments.







The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions